44 79

Cited 0 times in

Targeted Therapy of Hepatocellular Carcinoma Using Gemcitabine-Incorporated GPC3 Aptamer

Authors
 Jun Young Park  ;  Ju Ri Chae  ;  Ye Lim Cho  ;  Youndong Kim  ;  Dasom Lee  ;  Jeong Kyun Lee  ;  Won Jun Kang 
Citation
 PHARMACEUTICS, Vol.12(10) : E985, 2020-10 
Journal Title
 PHARMACEUTICS 
Issue Date
2020-10
Keywords
GPC3 ; aptamer ; aptamer-drug conjugate ; gemcitabine ; hepatocellular carcinoma
Abstract
Hepatocellular carcinoma (HCC) is the most common malignancy of the liver, which can progress rapidly and has a poor prognosis. Glypican-3 (GPC3) has been proposed to be an important diagnostic biomarker and therapeutic target for HCC. Aptamers have emerged as promising drug delivery vehicles because of their high binding affinity for target molecules. Herein, we developed G12msi, a gemcitabine-incorporated DNA aptamer, targeting GPC3, and evaluated its binding specificity and anti-tumor efficacy in GPC3-overexpressing HCC cell lines and murine xenograft models. GPC3-targeted aptamers were selected by using the SELEX process and the chemotherapy drug gemcitabine was internally incorporated into the aptamer. To determine the binding affinity and internalization of the G12msi, flow cytometry and confocal microscopy were performed on GPC3-positive HepG2, Hep3B, and Huh7 cells, as well as a GPC3-negative A431 cell. The anti-tumor activities of G12msi were evaluated with in vitro and in vivo models. We found that G12msi binds to GPC3-overexpressing HCC tumor cells with high specificity and is effectively internalized. Moreover, G12msi treatment inhibited the cell proliferation of GPC3-positive HCC cell lines with minimal cytotoxicity in control A431 cells. In vivo systemic administration of G12msi significantly inhibited tumor growth of HCC HepG2 cells in xenograft models without causing toxicity. These results suggest that gemcitabine-incorporated GPC3 aptamer-based drug delivery may be a promising strategy for the treatment of HCC.
Files in This Item:
T9992020019.pdf Download
DOI
10.3390/pharmaceutics12100985
Appears in Collections:
7. Others (기타) > Others (기타) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers
Yonsei Authors
Kang, Won Jun(강원준) ORCID logo https://orcid.org/0000-0002-2107-8160
Park, Jun Young(박준영) ORCID logo https://orcid.org/0000-0003-3403-2767
Cho, Ye Lim(조예림)
Chae, Ju Ri(채주리)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/179783
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links